Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10511428 | 1.00 | TDP1 (0.33) | TDP1TSHRALDH1A1 | |
| SCHEMBL10510379 | 1.00 | TDP1 (0.33) | TDP1TSHRALDH1A1 | |
| SCHEMBL10510127 | 1.00 | TDP1 (0.33) | TDP1TSHRALDH1A1 | |
| SCHEMBL10511703 | 1.00 | TDP1 (0.33) | TDP1TSHRALDH1A1 | |
| SCHEMBL755228 | 0.83 | TSHR (0.42) | TDP1TSHRALDH1A1 | |
| SCHEMBL3431727 | 0.83 | TDP1 (0.33) | TDP1TSHRALDH1A1 | |
| SCHEMBL5674520 | 0.82 | TSHR (0.32) | TDP1TSHR | |
| SCHEMBL10511725 | 0.81 | TSHR (0.31) | TDP1TSHR | |
| SCHEMBL10508861 | 0.81 | TSHR (0.31) | TDP1TSHR | |
| SCHEMBL10741886 | 0.81 | TSHR (0.31) | TDP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109553653-B | Panaxadiol glycoside derivative and preparation method and application thereof | 苏州济尔生物医药有限公司 | 2024-04-09 | — | — | CN | disclosed |
| WO-2021149587-A1 | METHOD FOR PRODUCING GLUCURONIC ACID | 池田食研株式会社 | 2021-07-29 | — | — | WO | disclosed |
| US-20100035857-A1 | ANTI-HYPERCHOLESTEROLEMIC COMPOUNDS | MERCK SHARP & DOHME CORP. | 2010-02-11 | — | — | US | disclosed |
| EP-2124549-A1 | ANTI-HYPERCHOLESTEROLEMIC COMPOUNDS | Merck & Co., Inc. (US) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008085300-A1 | ANTI-HYPERCHOLESTEROLEMIC COMPOUNDS | MERCK & CO., INC. (US) | 2008-07-17 | — | — | WO | disclosed |
| EP-1368363-A2 | SYNTHESIS OF CHLOROPHENOL RED GLUCORONIC ACID | Beckman Coulter, Inc. (US) | 2003-12-10 | — | — | EP | disclosed |
| EP-0864582-B1 | Hypolipidemic 1,4-benzothiazepine-1,-dioxides | AVENTIS PHARMA GMBH (DE) | 2003-06-04 | — | — | EP | disclosed |
| US-6534637-B2 | Generation of phenolsulphonphthalein glucuronic acid for use as tool in cancer diagnosis | BECKMAN COULTER, INC. | 2003-03-18 | — | — | US | disclosed |
| WO-2002064605-A2 | SYNTHESIS OF CHLOROPHENOL RED GLUCORONIC ACID | BECKMAN COULTER, INC. (US) | 2002-08-22 | — | — | WO | disclosed |
| US-20020115128-A1 | Synthesis of chlorophenol red glucuronic acid | BECKMAN COULTER, INC. | 2002-08-22 | — | — | US | disclosed |
| EP-0597915-B1 | A PROCESS FOR MAKING MORPHINE-6-GLUCURONIDE OR SUBSTITUTED MORPHINE-6-GLUCURONIDE | SALFORD ULTRAFINE CHEM & RES (GB) | 1998-11-11 | — | — | EP | disclosed |
| EP-0864582-A2 | Hypolipidemic 1,4-benzothiazepine-1,-dioxides | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-09-16 | — | — | EP | disclosed |
| US-5629339-A | CHRONIC VENOUS INSUFFICIENCY | ADIR ET COMPAGNIE (FR) | 1997-05-13 | — | — | US | disclosed |
| US-5621087-A | ANALGESICS | SALFORD ULTRAFINE CHEMICALS AND RESEARCH LIMITED (GB) | 1997-04-15 | — | — | US | disclosed |
| EP-0597915-A1 | A PROCESS FOR MAKING MORPHINE-6-GLUCURONIDE OR SUBSTITUTED MORPHINE-6-GLUCURONIDE | SALFORD ULTRAFINE CHEMICALS AND RESEARCH LIMITED (GB) | 1994-05-25 | — | — | EP | disclosed |
| US-5218097-A | PROCESS FOR THE PREPARATION OF PROTECTED MONO-SUGAR AND OLIGO-SUGAR HALIDES | CIBA-GEIGY CORPORATION (US) | 1993-06-08 | — | — | US | disclosed |
| WO-1993003051-A1 | A PROCESS FOR MAKING MORPHINE-6-GLUCURONIDE OR SUBSTITUTED MORPHINE-6-GLUCURONIDE | SALFORD ULTRAFINE CHEMICALS AND RESEARCH LIMITED (GB) | 1993-02-18 | — | — | WO | disclosed |
| EP-0373118-A2 | Process for the preparation of glycosyl halides of protected mono- and oligo-saccharides | CIBA-GEIGY AG (CH) | 1990-06-13 | — | — | EP | disclosed |
| EP-0173462-B1 | ELLIPTICINE DERIVATIVE AND PRODUCTION PROCESS THEREOF | SUNTORY LIMITED (JP) | 1989-10-25 | — | — | EP | disclosed |
| EP-0173462-A2 | Ellipticine derivative and production process thereof | SUNTORY LIMITED (JP) | 1986-03-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115128-A1 | Synthesis of chlorophenol red glucuronic acid | GUSB, UGT1A6, UGT1A7 | TDP1 3341/4885TSHR 407/4885ALDH1A1 268/4885 |
| US-20100035857-A1 | ANTI-HYPERCHOLESTEROLEMIC COMPOUNDS | NPC1L1, HMGCR, PCSK9 | TDP1 3893/4885TSHR 4729/4885ALDH1A1 909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.